FDA Experts Endorse Pioneering New Gene Therapy Treatment For Blindness

Wochit Headline News - Friday, 13 October 2017  (1 week ago)
A new ground-breaking gene therapy from Spark Therapeutics took a huge step towards FDA approval yesterday as a panel of experts offered their support for getting the treatment into the market. The vote was 16 to 0 favoring the benefit-risk profile of the drug, providing a compelling reason for the US FDA to approve the first US vector-delivered gene therapy.

Recent related news

SILVER SPRING, Md. (AP) β€” U.S. health advisers are reviewing a novel treatment for a rare form of inherited blindness, potentially setting the stage for the...
1 week ago • SeattlePI.com
Spark Therapeutics Inc. (NASDAQ:ONCE) shares surged in premarket trade after a U.S. Food and Drugs Administration advisory committee recommended approval of its...
1 week ago • Proactive Investors
Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma...
2 days ago • Wall Street Journal
SILVER SPRING, Md. (AP) β€” The Latest on an FDA panel's discussion on a gene therapy treatment for blindness (all times local): 3:19 p.m. U.S. health advisers...
1 week ago • SeattlePI.com
TRENTON, N.J. (AP) β€” U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma...
2 days ago • SeattlePI.com
TRENTON, N.J. (AP) β€” U.S. regulators have approved a second gene therapy for blood cancer. The one-time treatment is for aggressive lymphoma in adults. The...
2 days ago • SeattlePI.com

You might like